On June 1, 2021 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported that members of its senior management team will participate in a virtual event to discuss data from its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, as a monotherapy and in combination with nivolumab (Press release, Compugen, JUN 1, 2021, View Source [SID1234583354]). The data will be presented in an oral presenation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting, on June 7, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The vitual fireside chat, hosted by Asthika Goonewardene, Truist Securities Biotech Analyst, will take place on June 8, 2021 at 12:00 PM ET.
Participating on behalf of Compugen are Anat Cohen-Dayag, PhD, President and CEO; Ari Krashin, Chief Financial and Operating Officer; Henry Adewoye, PhD, Senior Vice President and Chief Medical Officer and Eran Ophir, PhD, Vice President, Research and Drug Discovery.
The event will also be available via live webcast through Compugen’s website, located at the following link.